ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Inventiva

Inventiva (IVA)

2.42
0.00
(0.00%)
Cerrado 27 Noviembre 10:30AM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
2.42
Postura de Compra
2.30
Postura de Venta
2.42
Volume Operado de la Acción
0.00
0.00 Rango del Día 0.00
1.434 Rango de 52 semanas 4.44
Capitalización de Mercado [m]
Precio Anterior
2.42
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
57,339
Acciones en circulación
210,670,845
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-4.62
Beneficio por acción (BPA)
-0.52
turnover
23.16M
Beneficio neto
-110.43M

Acerca de Inventiva

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sede
Daix, Fra
Fundado
-
Inventiva is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker IVA. The last closing price for Inventiva was 2.42 €. Over the last year, Inventiva shares have traded in a share price range of 1.434 € to 4.44 €.

Inventiva currently has 210,670,845 shares in issue. The market capitalisation of Inventiva is 509.82 € million. Inventiva has a price to earnings ratio (PE ratio) of -4.62.

IVA Últimas noticias

Inventiva publie ses informations financières du 3ème trimestre 2024¹

Inventiva publie ses informations financières du 3ème trimestre 2024¹ Trésorerie et équivalents de trésorerie à 13,9 millions d’euros au 30 septembre 2023.Chiffre d’affaires de 1,3 millions...

Inventiva reports 2024 Third Quarter Financial Information¹

Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an...

Inventiva reports 2024 Third Quarter Financial Information¹

Inventiva reports 2024 Third Quarter Financial Information¹ Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July...

Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024

Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode...

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024  

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024   Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code /...

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris...

Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires

Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires Daix (France), Long Island City (New York, Etats-Unis), le 20 novembre 2024 – Inventiva...

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of...

Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2

Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec...

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.175-6.743737957612.5952.5952.35172792.44304581DE
4-0.08-3.22.52.6352.31226432.49149537DE
120.2813.08411214952.143.21.434573392.29200572DE
26-0.74-23.4177215193.163.4951.434434422.4054228DE
52-1.29-34.77088948793.714.441.434499433.01389992DE
156-9.2-79.1738382111.6212.71.434535173.92682631DE
260-0.7-22.43589743593.1216.31.434641277.05677979DE

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ABEOABEO SA
9.76 €
(0.00%)
0
ABCAABC Arbitrage
4.81 €
(0.00%)
0
ABAb Science
0.775 €
(0.00%)
0
AALBAalberts NV
33.90 €
(0.00%)
0
AAAAlan Allman Associates
3.90 €
(0.00%)
0
ABEOABEO SA
9.76 €
(0.00%)
0
ABCAABC Arbitrage
4.81 €
(0.00%)
0
ABAb Science
0.775 €
(0.00%)
0
AALBAalberts NV
33.90 €
(0.00%)
0
AAAAlan Allman Associates
3.90 €
(0.00%)
0
ABEOABEO SA
9.76 €
(0.00%)
0
ABCAABC Arbitrage
4.81 €
(0.00%)
0
ABAb Science
0.775 €
(0.00%)
0
AALBAalberts NV
33.90 €
(0.00%)
0
AAAAlan Allman Associates
3.90 €
(0.00%)
0
worthylion worthylion 7 minutos hace
FTCO Been sliding lately as gold has declined a little despite 9%+ dividend yield. IMO Trump's presidency likely to be inflationary and create market uncertainty. A market "risk on" reaction to his election could turn into "risk off" after inauguration and increase the risk of an overdue correction.
FTCO
Steady_T Steady_T 11 minutos hace
Maybe. I'd rather see them spend their efforts on getting the NDA finished.

Having said that, there are a number of trials that I'd like to see get underway with Parkinson's being one of them.
AVXL
newflow newflow 13 minutos hace
lota WMI as a creditor has any claims against R?. Who is representing WMI as a creditor to R?.
COOP
Maximilliano Maximilliano 14 minutos hace
Trump's announcement said the council "will consist of all Departments and Agencies involved in the permitting, production, generation, distribution, regulation, transportation, of ALL forms of American Energy."

https://www.axios.com/2024/11/26/trump-ai-czar-role-elon-musk
FCEL
Dodger1 Dodger1 15 minutos hace
yep, all good as long as you have people to drive a car to the office building.

You all will figure it out in the end. Money...? Right..? Being..?

Go $AABB
AABB
Buellersback Buellersback 18 minutos hace
You most certainly are. It's very obvious and kind of disgusting. You are the reason this chat turned into a sh## show and everyone here knows it. The rest of the clowns joined in once you started the 'I'm just here for cheap entertainment" parade.
RGLG
thistraderknowsall thistraderknowsall 19 minutos hace
ZENA wakeup call for the shorts! $20 to $50 is next target ! Enjoy your margin covering !!
longago longago 22 minutos hace
Their PR is abysmal that is for damn sure.

If Ron does not at least glance at the comments here he is not learning anything.

Next week after Thanksgiving and after Q1 has ended I am going to try to engage him in a reasonable email conversation about some of the issues
RJDG
Ricorich Ricorich 24 minutos hace
style="font-size: 1.5em"AgEagle Aerial Systems Invited to the White House for Key Discussions on Commercial Unmanned Aerial Vehicles (UAVs)

https://ageagle.com/ageagle-aerial-systems-invited-to-the-white-house-for-key-discussions-on-commercial-unm
UAVS
Wolf-man jack Wolf-man jack 26 minutos hace
WQLF SAYS ; CVSI is still plugging along with three AcQisitions and more to come before CVSI gets AcQuired YQU WILL Then Understand YQU Understand. Have Mercy Have Faith Have Patience Have International Partners and M&A’s WQLF Ahooooooo

Gimminy Cricket 🦗 Said;

CVSI
Guzzi62 Guzzi62 26 minutos hace
No EU but UK!!
AVXL
jog49 jog49 32 minutos hace
Why? Because "sources" said so. LOL! It's amazing that people will buy into this BS.
FNMA
dinogreeves dinogreeves 34 minutos hace
Genius thought by someone on ST thread. He is right, especially with these tariffs, interest rates could go up.

"Paying off loans early for several strategic and financial reasons:

Paying off loans early can save the company money by avoiding future interest payments,
SMCI
lodas lodas 35 minutos hace
Your posts asserts WMI's position that it will abandon the ownership of WAMU's stock, and all rights , and the EQUITY IN THE STOCK!!!!!!!!......yet, ron makes the assertion that WMI placed 20.7 billion dollars in a Treasury Bill drawing interest, and is now worth over 27 billion dollars!!!!!.... how
JPM
dinogreeves dinogreeves 46 minutos hace
Very sad how people got robbed on this, grant it, only 660,000 volume, but is fair to say 300,000 shares got robbed and now some people are going to take a tax loss before the year is up. I wonder who was behind this move, company or frontloaders? They hyped it because of the low float, wow, just
TGLO
skitahoe skitahoe 47 minutos hace
I know this article was posted here, but I'd like to do it again and recommend the moderators consider stickying the article.

https://www.barchart.com/story/news/29772004/cancer-vaccines-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-dendreon-pharma-cande
NWBO
littlejohn littlejohn 49 minutos hace
Canada got their pipeline to west coast completed

and is shipping more oil overseas

from there in 2024...

They may not want to get dragged thru

more Keystone flip flops...

More rich going to D.C. don't care about
skitahoe skitahoe 51 minutos hace
The question in my mind is how long can they go without communicating with shareholders, and not be in trouble with the authorities. I know the OTC and Pinks are the Wild West of stock investment, and I have seen companies rise from the dead after years of not reporting, but I believe it cost them
CRTG
dinogreeves dinogreeves 52 minutos hace
They know they are financially a strong company, they know they are massively cash flow positive, more importantly, they know their business model is largely scalable, why else would they pay off their loans. Let's get the facts straight, this is not share selling scheme, this company is fundamenta
SMCI
lovethatgreen lovethatgreen 53 minutos hace
Up another billion wow

This is a waste of time
RDAR
dinogreeves dinogreeves 57 minutos hace
Late in the move, suggesting with the filings, SMCI is going make Hindenburg go bankrupt for trying to run their name through the mud. Big time redemption. Watch for press release tomorrow for the reason to payoff the notes is for financial flexibility. The only thing I want to know, how much mor
SMCI
XenaLives XenaLives 1 hora hace
B.S. and malfeasance liike this is the simplest expolanation for the heath crisis in this country.

$$$$ are much more important than quality of life or life expectancy of patients....

https://www.biospace.com/drug-development/mercks-former-asthma-blockbuster-singula